• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » iRhythm brings another Dexcom veteran into its C-suite

iRhythm brings another Dexcom veteran into its C-suite

July 18, 2022 By Sean Whooley

Portrait photo of iRhythm's next CCO Chad Patterson
iRhythm’s next CCO Chad Patterson [Image from Patterson’s LinkedIn page]
iRhythm Technologies (Nasdaq:IRTC) announced today that it appointed Chad Patterson as its next chief commercial officer.

Patterson will join the wearable electrocardiogram monitors developer’s executive leadership team and, as CCO, he will oversee the company’s commercial strategy, operations and execution.

He most recently served as chief marketing officer at Dexcom. He will make the move from the continuous glucose monitor developer to iRhythm just as president and CEO Quentin Blackford did in September of 2021.

“As iRhythm expands within its core U.S. markets, into additional international geographies, and into adjacent markets, we are excited to welcome Chad to our executive team,” Blackford said in a news release. “Chad joins us at the perfect time to leverage his experience in driving significant growth in global markets as we look to execute against our renewed corporate strategy. With his track record of execution and wealth of experience, his data-driven approach to sales and marketing strategies and operations will allow us to continue to evolve as a market leader in the space.”

Patterson will join the company following the resignation of Dave Vort, whose resignation will be made effective on July 25, 2022. Vort will continue to serve as a strategic advisor through March 31, 2023.

“We are grateful to Dave for his many contributions over the past eight and a half years, leading iRhythm from its early commercial days through periods of transformational growth,” Blackford said. “Dave was instrumental in building our world-class commercial organization and has played a key role in our ongoing success. We thank Dave for all that he has done for iRhythm and look forward to his continued contributions as a strategic advisor.”

While announcing the CCO transition, iRhythm also announced that it expects its upcoming quarterly earnings for the three months ended June 30 to be slightly ahead of expectations, with the company maintaining its projection of revenues between $410 million and $420 million for the full year.

“While preliminary, we are pleased with our second quarter volumes that demonstrated steady growth in our core U.S. market at rates slightly ahead of expectations as well as another quarter of record registrations,” Blackford said. We look forward to providing additional information during our second quarter 2022 earnings release in August.”

Filed Under: Business/Financial News, Cardiovascular, Diagnostics, Featured, Health Technology, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Dexcom, iRhythm Technologies, Personnel Moves

More recent news

  • Vicarious Surgical inks surgical robot collab with hospital, eyes first clinical patients
  • Bioliberty launches hub for soft-robotic wearable devices
  • Zynex submits laser pulse oximeter to FDA
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub
  • Product liability lawsuits target Medtronic, Boston Scientific spinal cord stim tech

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy